Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.

Détails

Ressource 1Télécharger: 30934986.pdf (447.24 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_D815E4DCBC60
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.
Périodique
Non-coding RNA
Auteur(s)
Gomes CPDC, Ágg B., Andova A., Arslan S., Baker A., Barteková M., Beis D., Betsou F., Wettinger S.B., Bugarski B., Condorelli G., Silva GJJD, Danilin S., Gonzalo-Calvo D., Buil A., Carmo-Fonseca M., Enguita F.J., Felekkis K., Ferdinandy P., Gyöngyösi M., Hackl M., Karaduzovic-Hadziabdic K., Hellemans J., Heymans S., Hlavackova M., Hoydal M.A., Jankovic A., Jusic A., Kardassis D., Kerkelä R., Kuster G.M., Lakkisto P., Leszek P., Lustrek M., Maegdefessel L., Martelli F., Novella S., O'Brien T., Papaneophytou C., Pedrazzini T., Pinet F., Popescu O., Potočnjak I., Robinson E., Sasson S., Scholz M., Simionescu M., Stoll M., Varga Z.V., Vinciguerra M., Xuereb A., Yilmaz M.B., Emanueli C., Devaux On Behalf Of The Eu-CardioRNA Cost Action Ca Y.
ISSN
2311-553X (Electronic)
ISSN-L
2311-553X
Statut éditorial
Publié
Date de publication
29/03/2019
Peer-reviewed
Oui
Volume
5
Numéro
2
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field.COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).
Mots-clé
best practices and guidelines, cardiovascular disease, personalized medicine, transcriptomics, translational research
Pubmed
Open Access
Oui
Création de la notice
15/04/2019 9:41
Dernière modification de la notice
20/08/2019 16:57
Données d'usage